Alterity (ATHE) news
Recent news
Alterity Therapeutics Limited: Ath434 50mg slowed MSA functional decline by about 52% vs placebo at week 52 - SEC filing
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) reported clinical results for its Phase 2 trial of ATH434 in patients with Multiple System Atrophy (MSA) in a recent SEC filing. The trial evaluated the efficacy of ATH434 at two dose levels (50 mg and 75 mg) compared to placebo over a 52-week…
AInvest Wire · Oct 5, 2026Alterity Therapeutics receives FDA end-of-Phase 2 meeting minutes confirming registrational pathway for ATH434 in multiple system atrophy
AInvest Wire · Jul 7, 2026Alterity Therapeutics: receives FDA end-of-phase 2 meeting minutes confirming registrational pathway for ATH434 in multiple system atrophy
Alterity Therapeutics has received minutes from its recent end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA), confirming a potential registrational pathway for ATH434 in the treatment of multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder. The…
AInvest Wire · Jul 7, 2026Alterity Therapeutics Ltd-FDA meeting minutes confirm registrational path for ATH434
Alterity Therapeutics Ltd. (ASX: ATH, NASDAQ: ATHE) has confirmed a clear regulatory pathway for its lead drug candidate, ATH434, following a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The meeting, held on June 9, 2026, aligned the company and the FDA…
AInvest Wire · Jul 6, 2026Alterity Therapeutics reports successful end-of-Phase 2 meeting with FDA
AInvest Wire · Jun 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.